Clinical Trials on Secondary Hyperparathyroidism (SHPT)

Total 1659 results

OPKO Health, Inc.

Withdrawn

Four Week, Pharmacodynamic/Pharmacokinetic, Efficacy, and Safety Study of Lunacalcipol (CTA018) (2007)

Secondary Hyperparathyroidism (SHPT) | Stage 5 Chronic Kidney Disease (CKD) | Hemodialysis (HD)
AbbVie

Recruiting

A Study to Evaluate Safety, Efficacy and Pharmacokinetics of Paricalcitol For Treatment of Secondary Hyperparathyroidism (SHPT) in Pediatric Participants With Stage 5 Chronic Kidney Disease (CKD)

Chronic Kidney Disease (CKD) | Secondary Hyperparathyroidism (SHPT)

United States, Puerto Rico
Shanghai Hengrui Pharmaceutical Co., Ltd.

Recruiting

Investigating the Safety and Efficacy of SHR6508 Injection in the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients : A Multicenter, Long-term Clinical Trial

Secondary Hyperparathyroidism (SHPT) in Subjects With Chronic Kidney Disease (CKD) on Hemodialysis

China
Postgraduate Institute of Medical Education and...

Unknown

Regulation of Vitamin D Receptor (VDR),Calcium Sensing Receptor (CaSR), Cyclin D1,Ki67 and Proliferating Cell Nuclear Antigen (PCNA) in Primary Hyperparathyroidism

Primary Hyperparathyroidism (PHPT)

India
The Second Hospital of Nanjing Medical University

Recruiting

Total Parathyroidectomy With Autotransplantation Versus Total Parathyroidectomy Alone for Secondary Hyperparathyroidism

Secondary Hyperparathyroidism;Parathyroidectomy

China
Phramongkutklao College of Medicine and Hospital

Completed

Effectiveness of Oral Alfacalcidol for Secondary Hyperparathyroidism in Chronic Hemodialysis Patients.

Alfacalcidol, Secondary Hyperparathyroidism, Hemodialysis
Chang Gung Memorial Hospital

Completed

Pulmonary Function, Voice and Swallowing Symptoms After Parathyroidectomy

Secondary Hyperparathyroidism Due to Renal Causes

Taiwan
Fundación Senefro
AbbVie; Effice Servicios Para la Investigacion S.L.

Completed

Efficacy and Safety of Paricalcitol in the Reduction of Secondary Hyperparathyroidism After Kidney Transplantation. (PARIDOINAL)

Secondary Hyperparathyroidism Due to Renal Causes

Spain
Min-Sheng General Hospital
Taipei Medical University; Taipei Medical University Shuang Ho Hospital; National... and other collaborators

Completed

Bone Markers and Bone Density Changes in Hyperperparathyroid Dialysis Patients Under Cinacalcet Treatment

Hyperparathyroidism; Secondary, Renal

Taiwan
Shanghai Zhongshan Hospital

Unknown

Preemptive and Precise Intervention for CKD-SHPT

Hyperparathyroidism; Secondary, Renal
Shanghai Hengrui Pharmaceutical Co., Ltd.

Active, not recruiting

A Study of SHR6508 in Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

China
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Phase 3 Study of SK-1403

Secondary Hyperparathyroidism

Japan
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

SK-1403 Long-term Treatment Study; Long-term Study in Patients With Secondary Hyperparathyroidism Receiving Hemodialysis

Secondary Hyperparathyroidism

Japan
Deltanoid Pharmaceuticals

Completed

A Phase 2A Dose-ranging and Pharmacokinetic Study of an Oral Vitamin D Compound (DP001) in Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

United States
Kyowa Kirin Co., Ltd.

Completed

Phase 3 Study of KHK7580

Secondary Hyperparathyroidism

Japan
KAI Pharmaceuticals

Completed

Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

United States
Penang Hospital, Malaysia
Ministry of Health, Malaysia

Unknown

Cinacalcet in Management of Secondary Hyperparathyroidism in Haemodialysis Patients

Secondary Hyperparathyroidism

Malaysia
Seoul National University Hospital
Jeil-Kirin Pharmaceutical Inc.

Completed

Cinacalcet stUdy for Peritoneal Dialysis Patients In Double Arm on the Lowing Effect OF iPTH Level (CUPID)

Secondary Hyperparathyroidism

Korea, Republic of
Kyowa Kirin Co., Ltd.

Completed

Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis

Hyperparathyroidism

Japan
Centre Hospitalier Universitaire de Saint Etienne
University Hospital, Geneva

Completed

Association Between Serum Periostin Levels and Cortical Porosity in Patients With Secondary Hyperparathyroidism

Hyperparathyroidism

France
Abbott
Statistika Consultoria Ltda

Terminated

Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis Subjects

Secondary Hyperparathyroidism | Dialysis

Brazil
China-Japan Friendship Hospital

Recruiting

Single-Cell Sequence Technology Used to Reveal Heterogeneity of Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

China
Kyowa Kirin Co., Ltd.
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.; Kyowa Kirin Korea Co., Ltd.

Completed

Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia

Secondary Hyperparathyroidism

China, Hong Kong, Korea, Republic of, Taiwan
Hospital General Ajusco Medio

Completed

IOPTH Usefulness for Predicting Successful Surgery in Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

Mexico
Kyowa Kirin Co., Ltd.

Completed

Phase 3 Study of KHK7580

Secondary Hyperparathyroidism

Japan
Kumamoto University

Completed

Maintenance Vitamin D Therapy for Secondary Hyperparathyroidism (2HPT)

Secondary Hyperparathyroidism

Japan
Kyowa Kirin Co., Ltd.

Completed

Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Peritoneal Dialysis

Secondary Hyperparathyroidism

Japan
Genzyme, a Sanofi Company

Completed

A Phase 4, Conversion Study of Hectorol® Injection to Hectorol® Capsules in Stage 5 CKD Patients on Dialysis

Secondary Hyperparathyroidism

United States
Amgen

Completed

Post Transplant Study

Hyperparathyroidism | Secondary Hyperparathyroidism | Kidney Tansplant
Sanwa Kagaku Kenkyusho Co., Ltd.

Completed

Dose Adjustment Trial of SK-1403 in Hemodialysis Patients With Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

Japan
Kyowa Kirin Co., Ltd.

Completed

Phase 2 Study of KHK7580

Secondary Hyperparathyroidism

Japan
Kyowa Kirin Co., Ltd.

Completed

Phase 3 Study of KHK7580

Secondary Hyperparathyroidism

Japan
Papageorgiou General Hospital

Terminated

Cinacalcet for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis

Secondary Hyperparathyroidism

Greece
Mersin University

Completed

Changes in Cardiac Functions in Patients Treated With Parathyroidectomy for Secondary Hyperparathyroidism

Secondary Hyperparathyroidism | Myocardial Dysfunction

Turkey
Wenhu Liu

Unknown

The Efficacy and Safety of Microwave Ablation for Mild-to-moderate Secondary Hyperparathyroidism Patients Undergoing Hemodialysis

Secondary Hyperparathyroidism | Maintenance Hemodialysis

China
Abbott

Completed

Efficacy and Safety of 6 Months Treatment With Paricalcitol Injection or Oral in Patients With Secondary Hyperparathyroidism on Dialysis

Secondary Hyperparathyroidism | Dialysis

Mexico
Fifth Affiliated Hospital, Sun Yat-Sen University

Completed

Diagnostic Accuracy of 3T MR for Secondary Hyperparathyroidism Comparison With 4DCT

Secondary Hyperparathyroidism | Parathyroid Gland Disease

China
National Center for Research Resources (NCRR)

Completed

Acute Regulation of Parathyroid Hormone by Dietary Phosphate

Secondary Hyperparathyroidism

United States
Beijing Friendship Hospital

Unknown

the Study on Prognostic for Hemodialysis Patients

Secondary Hyperparathyroidism

China
OPKO Health, Inc.

Completed

Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects

Secondary Hyperparathyroidism | Vitamin D Insufficiency

United States
Kyowa Hakko Kirin China Pharmaceutical Co., LTD.

Completed

Efficacy and Safety of Cinacalcet in Ca, P and iPTH Levels in Patients With Mild, Moderate and Severe SHPT (ACTIVE)

Hyperparathyroidism; Secondary, Renal

China
Josep M Cruzado

Completed

Parathyroidectomy vs Cinacalcet in the Treatment of Secondary Hyperparathyroidism Post Renal Transplantation

Secondary Hyperparathyroidism

Spain
Mario Negri Institute for Pharmacological Research

Completed

Paricalcitol in Reducing Parathyroid Hormone Levels and Ameliorating Markers of Bone Remodelling in Renal Transplant Recipients With Secondary Hyperparathyroidism (APPLE)

Renal Transplant | Secondary Hyperparathyroidism

Italy
Kerstyn C. Zalesin, M.D.
Abbott

Completed

Trial Of Paricalcitol and Cholecalciferol(Vitamin D3) in the Treatment Of Secondary Hyperparathyroidism in Patients After ROUX-EN-Y Gastric Bypass Surgery (ExtenD)

Gastric Bypass | Parathyroid Hormone

United States
University of Maryland, Baltimore

Completed

Suspected Deficient Activation of Vitamin D in Patients With Secondary Hyperparathyroidism (1hydroxylase)

Secondary Hyperparathyroidism

United States
Papageorgiou General Hospital

Completed

Initial Dosing of Paricalcitol in Secondary Hyperparathyroidism

Secondary Hyperparathyroidism
The Second Hospital of Anhui Medical University

Unknown

Comparison of Total Parathyroidectomy With and Without Autotransplantation

Secondary Hyperparathyroidism

China
Shanghai Hengrui Pharmaceutical Co., Ltd.

Completed

A Trial of SHR6508 in Secondary Hyperparathyroidism

Secondary Hyperparathyroidism

China
LEO Pharma

Completed

LEO 27847 - Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Study in Secondary Hyperparathyroidism Patients

Secondary Hyperparathyroidism

Germany, Poland
Amgen

Completed

A Phase 1 Study to Evaluate PK, Safety and Tolerability of AMG 416

Secondary Hyperparathyroidism

China

Clinical Trials on Secondary Hyperparathyroidism (SHPT)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations